Physician profile
Jaimie Glick
NPI 1114288214
$116,022.12
in general payments reported to CMS, 2019-2025
36 companies · $31K in 2025
The $31K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,125 · 2020: $2,981 · 2021: $1,011 · 2022: $10K · 2023: $25K · 2024: $44K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $87K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,498 · Food and Beverage: $3,977 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,444 · Travel and Lodging: $454 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $87,092.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,498.00 |
| Food and Beverage | $3,976.64 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,444.00 |
| Travel and Lodging | $454.43 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $97,685.58 | 2019-2025 | Xeomin |
| Sun Pharmaceutical Industries INC. | $9,176.04 | 2024-2025 | |
| Sandoz INC. | $2,300.00 | 2020 | |
| Abbvie INC. | $1,593.13 | 2020-2025 | |
| Galderma Laboratories, L.P. | $1,425.04 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Biofrontera INC. | $457.86 | 2019-2022 | |
| Allergan, INC. | $393.04 | 2019-2022 | |
| Janssen Biotech, INC. | $304.88 | 2019-2024 | Tremfya |
| Leo Pharma INC. | $289.64 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $279.44 | 2022-2025 | |
| Amgen INC. | $270.09 | 2021-2025 | Otezla |
| Genzyme Corporation | $241.15 | 2022-2025 | |
| Almirall LLC | $205.57 | 2019-2025 | Klisyri, Seysara |
| Lilly USA, LLC | $203.50 | 2019-2024 | Olumiant, Ebglyss, Taltz |
| Pfizer INC. | $160.51 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $137.10 | 2023-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $124.18 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $96.52 | 2023-2024 | Sotyktu |
| Ucb, INC. | $68.50 | 2020-2022 | |
| Dermavant Sciences, INC. | $66.11 | 2023-2024 | Vtama |
| Celgene Corporation | $60.75 | 2019 | |
| Incyte Corporation | $53.74 | 2024-2025 | Opzelura |
| Journey Medical Corporation | $50.56 | 2025 | |
| Dusa Pharmaceuticals, INC. | $41.42 | 2019 | |
| Revance Therapeutics, INC. | $40.91 | 2024 | Daxxify |
| Strata Skin Sciences, INC. | $29.55 | 2024-2025 | Xtrac |
| Organon LLC | $28.25 | 2025 | Vtama |
| Fidia Pharma USA INC. | $24.98 | 2024 | |
| Aclaris Therapeutics, INC. | $20.11 | 2019 | |
| Genentech USA, INC. | $19.98 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.33 | 2021 | |
| Botanix Sb INC | $13.66 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $11.92 | 2021 | |
| Mayne Pharma Commercial LLC | $9.08 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaimie Glick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.